Vistagen Therapeutics, Inc. (VTGN)

4.365 -0.02 (-0.57%) USD  |  NASDAQ  |  Dec 16, 16:00
4.35 -0.02 (-0.34%) After-Hours: 20:00
More

Vistagen Therapeutics Research and Development Expense (Annual): 39.38M for March 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for VTGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Vanda Pharmaceuticals, Inc. 74.43M
XOMA Royalty Corp. 2.875M
Omeros Corp. 119.52M
GeoVax Labs, Inc. 23.71M
Daré Bioscience, Inc. 14.21M